Patients & Caregivers
View All Conferences
NORD Breakthrough Summit 2015 | Page 2
Uveal Melanoma Cluster in Huntersville, NC
In Huntersville, North Carolina, there is a cluster of patients with uveal melanoma that may hold the key to finding out the cause for this cancer.
Genzyme's Mission: Diagnose Rare Disease Patients Earlier
Richard Peters, MD, PhD, head of the global rare disease business unit at Genzyme talks about some of the programs Genzyme is involved with to diagnose patients with rare diseases more quickly.
Alport Syndrome Foundation - Its Past, Present, and Future
Sharon Lagas, president of the Alport Syndrome Foundation talks about the history of the foundation, resources for Alport syndrome patients and upcoming Kidney Week plans
What is Ichthyosis?
Moureen Wenik of the Foundation for Ichthyosis and Related Skin Types (FIRST) talks about the disease, treatment options and resources that the foundation offers to physicians and patients.
Be Active, Be Visible, Be Heard
Bert Bruce of Pfizer talks about a session he chaired at the NORD Breakthrough Summit on how to get your message to your target audience.
Cure in Sight's OMG (Ocular Melanoma Getaway) Program
Zsa Zsa Stallings of Cure in Sight talks about their OMG (Ocular Melanoma Getaway) program that provides free vacations to families dealing with ocular melanoma.
DNA Sequencing and Cancer
Barbara Conley MD, associate director of the Cancer Diagnosis Program at the National Cancer Institute talks about the NCI-MATCH sequencing and exceptional response programs at the 2015 NORD Breakthrough Summit.
What is Alport Syndrome?
Sharon Lagas, president of the Alport Syndrome Foundation talks about the disease and possible treatments at the 2015 NORD Breakthrough Summit.
Susan Sherman, executive director of the LAM foundation describes the rare disease and the current treatment options for this devastating disease.
CDER's Janet Woodcock Discusses the Future of Drug Development
Janet Woodcock, MD, Director of CDER/FDA talks about the future of drug development, including the use of disease models.
<< Prev Page
Next Page >>
MOST POPULAR ARTICLES
FDA Expands Approval of Nucala to Include Treatment of Churg-Strauss Syndrome
Rare Disease Report: Five Facts About Rare Disease [Infographic]
IONIS-HTTrx Proves Effectiveness in Treating Cause of HD
Ralph Kern, M.D., Explains NurOwn as Potential ALS Therapy Moves Through the Pipeline
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.